- Home
- NRXP vs QNTM Comparison
NRXP vs QNTM Comparison
Compare NRXP & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- QNTM
- Stock Information
- Founded
- NRXP 2015
- QNTM 1998
- Country
- NRXP United States
- QNTM Canada
- Employees
- NRXP N/A
- QNTM N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- QNTM
- Sector
- NRXP Health Care
- QNTM
- Exchange
- NRXP Nasdaq
- QNTM NYSE
- Market Cap
- NRXP 32.6M
- QNTM 35.6M
- IPO Year
- NRXP N/A
- QNTM N/A
- Fundamental
- Price
- NRXP $2.90
- QNTM $13.77
- Analyst Decision
- NRXP Strong Buy
- QNTM
- Analyst Count
- NRXP 4
- QNTM 0
- Target Price
- NRXP $28.50
- QNTM N/A
- AVG Volume (30 Days)
- NRXP 378.9K
- QNTM 234.9K
- Earning Date
- NRXP 05-15-2025
- QNTM 05-14-2025
- Dividend Yield
- NRXP N/A
- QNTM N/A
- EPS Growth
- NRXP N/A
- QNTM N/A
- EPS
- NRXP N/A
- QNTM N/A
- Revenue
- NRXP N/A
- QNTM N/A
- Revenue This Year
- NRXP N/A
- QNTM N/A
- Revenue Next Year
- NRXP N/A
- QNTM N/A
- P/E Ratio
- NRXP N/A
- QNTM N/A
- Revenue Growth
- NRXP N/A
- QNTM N/A
- 52 Week Low
- NRXP $1.10
- QNTM $2.70
- 52 Week High
- NRXP $6.01
- QNTM $23.81
- Technical
- Relative Strength Index (RSI)
- NRXP 66.47
- QNTM 64.44
- Support Level
- NRXP $2.55
- QNTM $10.75
- Resistance Level
- NRXP $2.72
- QNTM $15.50
- Average True Range (ATR)
- NRXP 0.24
- QNTM 1.62
- MACD
- NRXP 0.02
- QNTM 0.22
- Stochastic Oscillator
- NRXP 80.00
- QNTM 69.50
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.